COMMUNIQUÉS West-GlobeNewswire

Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
09/04/2026
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for [...]
Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
09/04/2026
Results from the first-ever randomized control trial for the REGENETEN Implant in partial - thickness rotator cuff repair Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces [...]
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
09/04/2026
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s third major pharma [...]
Seres Therapeutics to Present at CARB-X Investor Day
09/04/2026
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X [...]
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
09/04/2026
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a [...]
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
09/04/2026
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S [...]
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
09/04/2026
KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., April 09, 2026 ( [...]
Nkarta to Participate in Needham Virtual Healthcare Conference
09/04/2026
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
09/04/2026
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, [...]
Soleo Health Opens New Ambulatory Infusion Center in Austin, Texas
09/04/2026
FRISCO, Texas and AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the opening of its new ambulatory [...]
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
09/04/2026
TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
09/04/2026
• Ecuador aims to become one of the first rabies free countries in Latin America. • Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance. • Boehringer [...]
Losing Your Voice? Millions Experience Persistent Problems Each Year
09/04/2026
ASHA Shares Warning Signs of Voice Disorders and Tips To Protect Your Voice for World Voice Day Rockville, MD, April 09, 2026 (GLOBE NEWSWIRE) -- Most people will experience an occasional sore throat related to a cold [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
09/04/2026
NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig ( [...]
Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
09/04/2026
First patient dosed in France, expanding the DOMISOL study beyond Australia DT ‑ 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program MONTREAL and [...]
Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
09/04/2026
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain cancer model that [...]
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
09/04/2026
Strengthens three community health models spanning community ‑ embedded care, earlier intervention and data ‑ driven population health Scales program footprint from 11 countries to more than 30 by 2030, including across [...]
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
09/04/2026
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical [...]
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
09/04/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global [...]

Pages